Company news
Rezolute, Inc. (NASDAQ:RZLT) news
Rezolute, Inc. news releases on 6ix. Latest, Apr 23, 2024: Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual…
Press releases — page 2
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
April 22, 2024
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
March 5, 2024
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
February 12, 2024
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
January 23, 2024
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
January 22, 2024
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
December 13, 2023
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
December 12, 2023
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
November 16, 2023
Rezolute Reports First Quarter Fiscal 2024 Results
November 12, 2023
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
October 16, 2023
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
October 10, 2023
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
September 13, 2023
Rezolute to Participate in Upcoming Investor Conferences in September
September 5, 2023
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
June 26, 2023
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
May 10, 2023
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
March 22, 2023
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
March 7, 2023
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
February 9, 2023
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
December 14, 2022
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
November 8, 2022
Rezolute to Present at the Jefferies London Healthcare Conference
October 31, 2022
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
October 19, 2022
Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress
September 14, 2022
Rezolute Announces Presentation at the 60th Annual ESPE Meeting
September 6, 2022
Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
May 31, 2022
Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
May 11, 2022
Rezolute to Host Corporate Update Call on May 4, 2022
May 3, 2022
Rezolute, Inc. Announces Closing of Registered Direct Offering
May 3, 2022
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
April 30, 2022
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
April 30, 2022
RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022
April 25, 2022
Rezolute Joins the Rare Disease Company Coalition
March 28, 2022
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
March 22, 2022
Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME
February 21, 2022
Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress
February 8, 2022
Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
November 11, 2021
Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
October 12, 2021
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
October 11, 2021
Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
September 21, 2021
Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
September 14, 2021
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism
September 8, 2021
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
September 6, 2021
Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME
August 9, 2021
Rezolute Added to Russell Microcap® Index
June 27, 2021
Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs
May 19, 2021
Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board
May 17, 2021
Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit
May 16, 2021
Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress
May 16, 2021
Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema
May 3, 2021
Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners
April 18, 2021